Changes in aminergic receptors in a PSP postmortem brain: correlation with pathological findings

  • J. Pascual
  • J. Figols
  • B. Grijalba
  • A. M. González
  • E. del Olmo
  • J. Berciano
  • A. Pazos
Part of the Journal of Neural Transmission. Supplementa book series (NEURAL SUPPL, volume 42)


The state of different aminergic receptors was assessed, by quantitative autoradiography in tissue sections, in several representative brain regions from a typical progressive supranuclear palsy (PSP) patient and from 9 matched brains. The densities of muscarinic receptors were within control limits in most of the brain areas of this PSP brain. Serotonin1 receptors were clearly reduced only in areas with very relevant neuropatho-logical damage, such as locus niger and globus pallidus. The density of D1 dopamine receptors in the caudate-putamen and frontal cortex of the patient was within control limits. By contrast, nigral D1 and striatal D2 dopamine receptors were dramatically reduced in the patient as compared to controls. Finally, alpha2-adrenoceptors were clearly reduced in all the examined areas of this PSP patient as compared to control group. Both the potential role of these receptor changes in the pathophysiology of the clinical features of PSP and their correlation with the neuropathological findings of this PSP patient are discussed.


Dopamine Receptor Progressive Supranuclear Palsy Progressive Supranuclear Palsy Locus Ceruleus Neurofibrillary Degeneration 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Agid Y, Javoy-Agid F, Ruberg M (1987) Biochemistry of neurotransmitters in Parkinson’s disease. In: Marsden CD, Fahn S (eds) Movement disorders, vol 2. Butterworths, London, pp 166–230.Google Scholar
  2. Baron JC, Mazière B, Loc’h C, Sgouropoulos P, Bonnet AM, Agid Y (1985) Progressive supranuclear palsy: loss of striatal dopamine receptors demonstrated in vivo by positron tomography. Lancet i: 1163–1164.CrossRefGoogle Scholar
  3. Barr AN (1986) Progressive supranuclear palsy. In: Vinken PJ, Bruyn GW, Klawans HL (eds) Handbook of clinical neurology, vol 49. Extrapyramidal disorders. Elsevier, Amsterdam, pp 239–254.Google Scholar
  4. Bokobza B, Ruberg M, Scaton B, Javoy-Agid F, Agid Y (1984) [3H]spiperone binding, dopamine and HVA concentrations in Parkinson’s disease and supranuclear palsy. Eur J Pharmacol 99: 167–175.PubMedCrossRefGoogle Scholar
  5. Bondareff W, Mountjoy CQ, Roth M (1981) Selective loss of neurons of origin of adrenergic projection to cerebral cortex (nucleus locus coeruleus) in senile dementia. Lancet i: 783–784.CrossRefGoogle Scholar
  6. Brooks DJ, Ibanez V, Sawle GV, Playford ED, Quinn N, Nathias CJ, Lees AJ, Marsden CD, Bannister R, Frackowiak SJ (1992) Striatal D2 receptor status in patients with Parkinson’s disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11C-raclopride and positron emission tomography. Ann Neurol 31: 184–192.PubMedCrossRefGoogle Scholar
  7. Camps M, Cortés R, Gueye B, Probst A, Palacios JM (1989) Dopamine receptors in human brain: autoradiographic distribution of D2 sites. Neuroscience 28: 275–290.PubMedCrossRefGoogle Scholar
  8. Cash R, Ruberg M, Raisman R, Agid Y (1984) Adrenergic receptors in Parkinson’s disease. Brain Res 322: 269–275.PubMedCrossRefGoogle Scholar
  9. Charney DS, Heninger GR, Sternberg DE (1983) Alpha2-adrenergic receptor sensitivity and the mechanism of action of antidepressant therapy: the effect of longterm amitriptyline treatment. Br J Psychiatry 142: 265–275.PubMedCrossRefGoogle Scholar
  10. Cortés R, Camps M, Gueye B, Probst A, Palacios JM (1989a) Dopamine receptors in human brain: autoradiographic distribution of D1 and D2 sites in Parkinson syndrome of different etiology. Brain Res 483: 30–38.PubMedCrossRefGoogle Scholar
  11. Cortés R, Gueye B, Pazos A, Probst A, Palacios JM (1989b) Dopamine receptors in human brain: autoradiographic distribution of D1 sites. Neuroscience 28: 263–273.PubMedCrossRefGoogle Scholar
  12. Cortés R, Probst A, Palacios JM (1984) Quantitative light microscopic autoradiographic localization of cholinergic muscarinic receptors in the human brain: brainstem. Neuroscience 12: 1003–1026.PubMedCrossRefGoogle Scholar
  13. Ghika AJ, Tennis M, Schoenfield D, Growdon JH (1991) Idazoxan improves motor function in progressive supranuclear palsy. Neurology 41[Suppl 1]: 173.Google Scholar
  14. Guttmann M, Seeman P, Reynolds GP, Riederer P, Jellinger K, Tourtellote WW (1986) Dopamine D2 receptor density remains constant in treated Parkinson’s disease. Ann Neurol 19: 487–492.CrossRefGoogle Scholar
  15. Hoyer D, Waeber C, Pazos A, Probst A, Palacios JM (1988) Identification of a 5-HT1 recognition site in human brain membranes different from 5-HT1A, 5-HT1B and 5-HT1C sites. Neurosci Lett 85: 357–362.PubMedCrossRefGoogle Scholar
  16. Jankovic J (1984) Progressive supranuclear palsy: clinical and pharmacological update. Neurol Clin 2: 473–486.PubMedGoogle Scholar
  17. Jellinger K (1987) The pathology of parkinsonism. In: Marsden CD, Fahn S (eds) Movement disorders, vol 2. Butterworths, London, pp 124–165.Google Scholar
  18. Kish SJ, Chang LJ, Mirchandani L, Shannak K, Hornykiewicz O (1985) Progressive supranuclear palsy: relationship between extrapyramidal disturbances, dementia, and brain neurotransmitter markers. Ann Neurol 18: 530–536.PubMedCrossRefGoogle Scholar
  19. Klawans HL, Ringel SP (1978) Observations on the efficacy of L-dopa in progressive supranuclear palsy. J Can Sci Neurol 5: 167–173.Google Scholar
  20. Mann DMA, Yates PO, Hawkes J (1983) The pathology of the human locus coeruleus. Clin Neuropathol 2: 1–7.PubMedGoogle Scholar
  21. Matsuo H, Takashima H, Kishikawa M, Kinoshita I, Mori M, Tsujihata M, Nagataki S (1991) Pure akinesia: an atypical manifestation of progressive supranuclear palsy. J Neurol Neurosurg Psychiatry 54: 397–400.PubMedCrossRefGoogle Scholar
  22. Meana JJ, Barturen F, Asier M, Garcia-Sevilla JA, Fontán A, Zarranz JJ (1992) Decreased density of presynaptic alpha2-adrenoceptors in postmortem brains of patients with Alzheimer’s disease. J Neurochem 58: 1896–1904.PubMedCrossRefGoogle Scholar
  23. Oyanagi K, Takahashi H, Wakabayashi K, Ikuta F (1988) Selective decrease of large neurons in the neostriatum in progressive supranuclear palsy. Brain Res 458: 218–223.PubMedCrossRefGoogle Scholar
  24. Pascual J, Berciano J, Grijalba B, del Olmo E, González AM, Figols J, Pazos A (1992a) Dopamine D1 and D2 receptors in progressive supranuclear palsy: an autoradiographic study. Ann Neurol 32: 703–707.PubMedCrossRefGoogle Scholar
  25. Pascual J, Berciano J, González AM, Grijalba B, Figols J, Pazos A (1993) Autoradiographic demonstration of loss of alpha2-adrenoceptors in progressive supranuclear palsy. Preliminary report. J Neurol Sci 114: 165–169.PubMedCrossRefGoogle Scholar
  26. Pascual J, del Arco C, González AM, Pazos A (1992b) Quantitative light microscopic autoradiographic localization of alpha2-adrenoceptors in the human brain. Brain Res 585: 116–127.PubMedCrossRefGoogle Scholar
  27. Pascual J, Grijalba B, García-Sevilla J, Zarranz JJ, Pazos A (1992c) Loss of high-affinity alpha2-adrenoceptors in Alzheimer’s disease: an autoradiographic study in frontal cortex and hippocampus. Neurosci Lett 142: 36–40.PubMedCrossRefGoogle Scholar
  28. Pascual J, Pazos A, del Olmo E, Figols J, Leno C, Berciano J (1991) Presynaptic parkinsonism in olivopontocerebellar atrophy: clinical, pathological and neuroch-emical evidence. Ann Neurol 30: 425–428.PubMedCrossRefGoogle Scholar
  29. Pazos A, González AM, Pascual J, Meana JJ, Barturen F, García-Sevilla JA (1988) Alpha2-adrenoceptors in human forebrain: autoradiographic visualization and biochemical parameters using tha agonist 3H-UK 14304. Brain Res 475: 361–365.PubMedCrossRefGoogle Scholar
  30. Pazos A, Probst A, Palacios JM (1987) Serotonin receptors in the human brain-III. Autoradiographic mapping of serotonin-1 receptors. Neuroscience 21: 97–122.PubMedCrossRefGoogle Scholar
  31. Pazos A, Palacios JM (1985) Quantitative autoradiographic mapping of serotonin receptors in the rat brain. I. Serotonin-1 receptors. Brain Res 346: 205–230.PubMedCrossRefGoogle Scholar
  32. Pierot L, Desnos C, Blin J, Raisman R, Scherman D, Javoy-Agid F, Ruberg M, Agid Y (1988) D1 and D2-type dopamine receptors in patients with Parkinson’s disease and progressive supranuclear palsy. J Neurol Sci 86: 291–306.PubMedCrossRefGoogle Scholar
  33. Pimoule C, Schoemacker H, Reynolds GP, Langer SZ (1985) 3H-SCH 23390 labeled D1 receptors are unchanged in schizophrenia and Parkinson’s disease. Eur J Pharmacol 114: 235–237.PubMedCrossRefGoogle Scholar
  34. Raisman R, Cash Ruberg M (1985) Binding of 3H-SCH 23390 to D1 receptors in the putamen of control and parkinsonian subjects. Eur J Pharmacol 113: 467–468.PubMedCrossRefGoogle Scholar
  35. Rinne JO, Rinne JK, Laakso K, Lönnberg P, Rinne UK (1985) Dopamine D1 receptors in the parkinsonian brain. Brain Res 359: 306–310.PubMedCrossRefGoogle Scholar
  36. Robertson HA (1992) Dopamine receptor interactions: some implications for the treatment of Parkinson’s disease. Trends Neurosci 15: 201–206.PubMedCrossRefGoogle Scholar
  37. Ruberg M, Javoy-Agid F, Hirsch E, Scatton B, LHeureux R, Hauw JJ, Duyckaerts C, Gray F, Morel-Maroger A, Rascol A, Serdaru M, Agid Y (1985) Dopaminergic and cholinergic lesions in progressive supranuclear palsy. Ann Neurol 18: 523–529.PubMedCrossRefGoogle Scholar
  38. Schwarz J, Tastsch K, Arnold G, Gasser T, Trenkwalder C, Kirsch CM, Oertel WH (1992) 123I-iodobenzamide-SPECT predicts dopaminergic responsiveness in patients with de novo parkinsonism. Neurology 42: 556–561.PubMedCrossRefGoogle Scholar
  39. Starke K, Gothert M, Kilbinger H (1989) Modulation of neurotransmitter release by presynaptic autoreceptors. Physiol Rev 69: 864–989.PubMedGoogle Scholar
  40. Steele JC (1972) Progressive supranuclear palsy. Brain 95: 693–704.PubMedGoogle Scholar
  41. Steele JC (1975) Progressive supranuclear palsy. In: Vinken PJ, Bruyn GW (eds) Handbook of clinical neurology, vol 22. System disorders and atrophies. North-Holland, Amsterdam, pp 217–230.Google Scholar
  42. Steele JC, Richardson JC, Olzsewski J (1964) Progressive supranuclear palsy: a heterogeneous degeneration involving the brainstem, basal ganglia and cerebellum with vertical gaze and pseudobulbar palsy, nuchal dystonia and dementia. Arch Neurol 10: 333–359.PubMedCrossRefGoogle Scholar
  43. Unnerstall JR, Niehoff DL, Kuhar MJ, Palacios JM (1982) Quantitative receptor autoradiography using [3H]-Ultrofllm. J Neurosci Methods 6: 59–73.PubMedCrossRefGoogle Scholar
  44. Waeber C, Dietl MM, Hoyer D, Probst A, Palacios JM (1988) Visualization of a novel serotonin recognition site (5-HT1D) in the human brain by autoradiography. Neurosci Lett 88: 11–16.PubMedCrossRefGoogle Scholar
  45. Wienhard K, Coenen HH, Pawlik G, Rudolf J, Laufer P, Jovkar S, Stocklin G (1990) PET studies of dopamine receptor distribution using [18F]fluoroethylspiperone: findings in disorders related to the dopaminergic system. J Neural Transm 81: 195–213.CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Wien 1994

Authors and Affiliations

  • J. Pascual
    • 1
    • 2
    • 4
  • J. Figols
    • 3
  • B. Grijalba
    • 1
  • A. M. González
    • 1
  • E. del Olmo
    • 1
  • J. Berciano
    • 2
  • A. Pazos
    • 1
  1. 1.Department of Physiology and Pharmacology, Unit of PharmacologyUniversity of CantabriaSantanderSpain
  2. 2.Service of NeurologyUniversity of CantabriaSantanderSpain
  3. 3.Section of Neuropathology, University Hospital “Marqués de Valdecilla”University of CantabriaSantanderSpain
  4. 4.Neurology ServiceUniversity Hospital “Marqués de Valdecilla”SantanderSpain

Personalised recommendations